Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29982629 | 1.00 | MAOB (0.54) | MAOBMAOAPBRM1LMNAMAPT | |
| Formaldehyde SCHEMBL28160192 | 0.96 | MAOB (0.51) | MAOBMAOAPBRM1LMNAMAPT | |
| SCHEMBL989569 | 0.89 | PBRM1 (0.47) | MAOBMAOAPBRM1LMNAMAPT | |
| SCHEMBL2066249 | 0.85 | MAOB (0.64) | MAOBMAOALMNAMAPTHTT | |
| SCHEMBL29825555 | 0.85 | MAOB (0.64) | MAOBMAOALMNAMAPTHTT | |
| Formaldehyde SCHEMBL28233549 | 0.82 | MAOB (0.60) | MAOBMAOALMNAMAPTHTT | |
| SCHEMBL27942636 | 0.82 | MAOB (0.60) | MAOBMAOALMNAMAPTHTT | |
| SCHEMBL7991966 | 0.82 | MAOB (0.51) | MAOBMAOAPBRM1LMNAMAPT | |
| SCHEMBL2981516 | 0.81 | MAOB (0.74) | MAOBMAOAPBRM1MAPTGRM5 | |
| SCHEMBL29706440 | 0.81 | APP (0.55) | PBRM1LMNAMAPTHTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-12350270-B2 | Antimalarial agents | MSD R&D (CHINA) CO. LTD. (CN) | 2025-07-08 | — | — | US | disclosed |
| WO-2025108255-A1 | POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-119894878-A | Aromatic amide derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-0228172-A1 | Preparation of 6-substituted 4-chromanones | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1987-07-08 | — | — | EP | disclosed |
| EP-0117675-B1 | BENZOFURAN AND BENZOTHIOPHENE-CARBOXYLIC-ACID DERIVATIVES | BEECHAM GROUP PLC (GB) | 1986-07-23 | — | — | EP | disclosed |
| US-4548948-A | Anti-inflammatory and analgesic benzothiophene and benzafuran derivatives, compositions, and method of use therefor | BEECHAM GROUP P.L.C. (GB) | 1985-10-22 | — | — | US | disclosed |
| EP-0117675-A1 | Benzofuran and benzothiophene-carboxylic-acid derivatives | BEECHAM GROUP PLC (GB) | 1984-09-05 | — | — | EP | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | MAOB 2121/4885MAOA 2129/4885PBRM1 1999/4885 |
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | MAOB 2174/4885MAOA 2893/4885PBRM1 1406/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | MAOB 3044/4885MAOA 2511/4885PBRM1 2127/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | MAOB 975/4885MAOA 2223/4885PBRM1 18/4885 |
| US-12350270-B2 | Antimalarial agents | CTSL, SERPINA3, SERPINB1 | MAOB 2711/4885MAOA 2693/4885PBRM1 2545/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | MAOB 857/4885MAOA 924/4885PBRM1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.